XML 89 R71.htm IDEA: XBRL DOCUMENT
v3.3.1.900

OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Details) | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2015 USD ($) | Sep. 30, 2015 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Sep. 30, 2014 USD ($) | Jun. 30, 2014 USD ($) | Mar. 31, 2014 USD ($) | Sep. 30, 2014 USD ($) | Dec. 31, 2015 USD ($) segment | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($)
Segment information |  |  |  |  |  |  |  |  |  |  |  |
Number of business segments | segment |  |  |  |  |  |  |  |  |  | 4 |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue | $ 79,994,000 | $ 79,586,000 | $ 81,247,000 | $ 83,878,000 | $ 86,663,000 | $ 93,406,000 | $ 92,831,000 | $ 93,467,000 |  | $ 324,705,000 | $ 366,367,000 | $ 369,826,000
Contribution margin: |  |  |  |  |  |  |  |  |  |  |  |
Total contribution margin |  |  |  |  |  |  |  |  |  | 121,574,000 | 138,975,000 | 141,966,000
Selling, general and administrative | 26,865,000 | 27,115,000 | 27,392,000 | 26,330,000 | 30,634,000 | 30,200,000 | 29,941,000 | 29,152,000 |  | 107,702,000 | 119,927,000 | 118,383,000
Operating income | 2,220,000 | 3,138,000 | 3,184,000 | 5,330,000 | 834,000 | 5,546,000 | 5,827,000 | 6,841,000 |  | 13,872,000 | 19,048,000 | 23,583,000
Other income (expense) | (25,000) | (247,000) | (2,000) | (318,000) | 349,000 | (42,000) | (79,000) | (262,000) |  | (592,000) | (34,000) | 1,993,000
Income from continuing operations before provision for income taxes | 2,195,000 | $ 2,891,000 | $ 3,182,000 | $ 5,012,000 | 1,183,000 | 5,504,000 | $ 5,748,000 | $ 6,579,000 |  | 13,280,000 | 19,014,000 | 25,576,000
Capital expenditures: |  |  |  |  |  |  |  |  |  |  |  |
Total capital expenditures |  |  |  |  |  |  |  |  |  | 22,226,000 | 26,910,000 | 8,556,000
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Total depreciation and amortization |  |  |  |  |  |  |  |  |  | 4,525,000 | 4,409,000 | 4,466,000
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Total Assets | 200,520,000 |  |  |  | 196,799,000 |  |  |  |  | 200,520,000 | 196,799,000 |
Property, plant and equipment |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment | 68,728,000 |  |  |  | 51,343,000 |  |  |  |  | 68,728,000 | 51,343,000 |
Impairment charge |  |  |  |  |  |  |  |  |  | 0 | 2,947,000 | 0
Subsidiary in Venezuela |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment |  |  |  |  |  | $ 0 |  |  | $ 0 |  |  |
Impairment charge |  |  |  |  |  |  |  |  | $ 2,900,000 |  |  |
United States |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 147,553,000 | 148,219,000 | 152,209,000
Property, plant and equipment |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment | 66,044,000 |  |  |  | 48,013,000 |  |  |  |  | 66,044,000 | 48,013,000 |
Other |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 128,676,000 | 163,834,000 | 183,410,000
Property, plant and equipment |  |  |  |  |  |  |  |  |  |  |  |
Total property, plant and equipment | 2,684,000 |  |  |  | 3,330,000 |  |  |  |  | 2,684,000 | 3,330,000 |
South Korea (Synergy) |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 48,476,000 | 54,314,000 | 34,207,000
NSP Americas |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 179,151,000 | 182,395,000 | 190,684,000
Contribution margin: |  |  |  |  |  |  |  |  |  |  |  |
Total contribution margin |  |  |  |  |  |  |  |  |  | 74,953,000 | 74,603,000 | 78,171,000
Capital expenditures: |  |  |  |  |  |  |  |  |  |  |  |
Total capital expenditures |  |  |  |  |  |  |  |  |  | 21,437,000 | 25,581,000 | 8,018,000
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Total depreciation and amortization |  |  |  |  |  |  |  |  |  | 3,603,000 | 3,438,000 | 3,568,000
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Total Assets | 141,428,000 |  |  |  | 129,371,000 |  |  |  |  | 141,428,000 | 129,371,000 |
NSP Americas | General health |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 80,315,000 | 78,218,000 | 80,379,000
NSP Americas | Immune |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 22,042,000 | 23,549,000 | 23,374,000
NSP Americas | Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 12,331,000 | 12,566,000 | 13,018,000
NSP Americas | Digestive |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 49,239,000 | 53,133,000 | 55,936,000
NSP Americas | Personal care |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 3,575,000 | 4,000,000 | 5,162,000
NSP Americas | Weight management |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 11,649,000 | 10,929,000 | 12,815,000
NSP Russia, Central and Eastern Europe |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 27,408,000 | 50,274,000 | 62,747,000
Contribution margin: |  |  |  |  |  |  |  |  |  |  |  |
Total contribution margin |  |  |  |  |  |  |  |  |  | 9,474,000 | 17,851,000 | 22,542,000
Capital expenditures: |  |  |  |  |  |  |  |  |  |  |  |
Total capital expenditures |  |  |  |  |  |  |  |  |  | 0 | 8,000 | 4,000
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Total depreciation and amortization |  |  |  |  |  |  |  |  |  | 26,000 | 25,000 | 27,000
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Total Assets | 5,122,000 |  |  |  | 6,679,000 |  |  |  |  | 5,122,000 | 6,679,000 |
NSP Russia, Central and Eastern Europe | General health |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 11,433,000 | 18,841,000 | 22,690,000
NSP Russia, Central and Eastern Europe | Immune |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 3,328,000 | 6,512,000 | 7,902,000
NSP Russia, Central and Eastern Europe | Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 1,714,000 | 3,104,000 | 4,324,000
NSP Russia, Central and Eastern Europe | Digestive |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 7,167,000 | 13,171,000 | 15,693,000
NSP Russia, Central and Eastern Europe | Personal care |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 2,716,000 | 6,073,000 | 8,817,000
NSP Russia, Central and Eastern Europe | Weight management |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 1,050,000 | 2,573,000 | 3,321,000
Synergy WorldWide |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 114,081,000 | 128,101,000 | 108,290,000
Contribution margin: |  |  |  |  |  |  |  |  |  |  |  |
Total contribution margin |  |  |  |  |  |  |  |  |  | 35,277,000 | 43,888,000 | 38,011,000
Capital expenditures: |  |  |  |  |  |  |  |  |  |  |  |
Total capital expenditures |  |  |  |  |  |  |  |  |  | 302,000 | 1,321,000 | 534,000
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Total depreciation and amortization |  |  |  |  |  |  |  |  |  | 885,000 | 946,000 | 871,000
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Total Assets | 38,048,000 |  |  |  | 40,797,000 |  |  |  |  | 38,048,000 | 40,797,000 |
Synergy WorldWide | General health |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 43,829,000 | 46,546,000 | 36,723,000
Synergy WorldWide | Immune |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 752,000 | 974,000 | 1,394,000
Synergy WorldWide | Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 34,191,000 | 42,449,000 | 42,154,000
Synergy WorldWide | Digestive |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 17,746,000 | 20,839,000 | 16,897,000
Synergy WorldWide | Personal care |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 5,697,000 | 7,196,000 | 7,097,000
Synergy WorldWide | Weight management |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 11,866,000 | 10,097,000 | 4,025,000
China and New Markets |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 4,065,000 | 5,597,000 | 8,105,000
Contribution margin: |  |  |  |  |  |  |  |  |  |  |  |
Total contribution margin |  |  |  |  |  |  |  |  |  | 1,870,000 | 2,633,000 | 3,242,000
Capital expenditures: |  |  |  |  |  |  |  |  |  |  |  |
Total capital expenditures |  |  |  |  |  |  |  |  |  | 487,000 | 0 | 0
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Total depreciation and amortization |  |  |  |  |  |  |  |  |  | 11,000 | 0 | 0
Assets: |  |  |  |  |  |  |  |  |  |  |  |
Total Assets | $ 15,922,000 |  |  |  | $ 19,952,000 |  |  |  |  | 15,922,000 | 19,952,000 |
China and New Markets | General health |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 1,903,000 | 2,370,000 | 3,259,000
China and New Markets | Immune |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 525,000 | 777,000 | 1,006,000
China and New Markets | Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 292,000 | 334,000 | 461,000
China and New Markets | Digestive |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 1,011,000 | 1,608,000 | 2,365,000
China and New Markets | Personal care |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | 93,000 | 108,000 | 126,000
China and New Markets | Weight management |  |  |  |  |  |  |  |  |  |  |  |
Net sales revenue: |  |  |  |  |  |  |  |  |  |  |  |
Total net sales revenue |  |  |  |  |  |  |  |  |  | $ 241,000 | $ 400,000 | $ 888,000
Nature's Sunshine Products |  |  |  |  |  |  |  |  |  |  |  |
Segment information |  |  |  |  |  |  |  |  |  |  |  |
Number of business segments | segment |  |  |  |  |  |  |  |  |  | 2 |  |

X
- References No definition available. + Details
Name: | natr_AdditionsToNoncurrentAssetsAbstract
Namespace Prefix: | natr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of contribution margin which consists of net sales revenue less cost of sales and volume incentives expense. + References No definition available. + Details
Name: | natr_ContributionMargin
Namespace Prefix: | natr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | natr_ContributionMarginAbstract
Namespace Prefix: | natr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DepreciationAndAmortizationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 225 -Section 45 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51659069&loc=d3e92212-112881 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Impairment -URI http://asc.fasb.org/extlink&oid=6515133 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51824106&loc=d3e2420-110228 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsHeldForUse
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + References No definition available. + Details
Name: | us-gaap_NumberOfReportableSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 + Details
Name: | us-gaap_PropertyPlantAndEquipmentNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311 + Details
Name: | us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=natr_SubsidiaryInVenezuelaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=natr_OtherCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_KR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=natr_NaturesSunshineProductsAmericasAsiaPacificAndEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_GeneralHealthProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_ImmunityProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_CardiovascularProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_DigestiveProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_PersonalCareProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=natr_WeightManagementProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=natr_NaturesSunshineProductsRussiaCentralAndEasternEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=natr_SynergyWorldWideBrandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=natr_ChinaAndNewMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=natr_NaturesSunshineProductsBrandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |